CeriBell (NASDAQ:CBLL) Receives $31.00 Average PT from Brokerages

CeriBell (NASDAQ:CBLL) has been given a consensus rating of “Buy” by the six research firms that are covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have issued a report on the stock in the last year is $31.00.

CBLL has been the topic of several recent analyst reports. William Blair assumed coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set an “outperform” rating on the stock. Bank of America began coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on CeriBell in a research report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 target price for the company. TD Cowen assumed coverage on CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $31.00 target price on the stock. Finally, Canaccord Genuity Group began coverage on shares of CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price target for the company.

CeriBell Trading Down 2.3 %

Shares of CBLL stock opened at $28.27 on Tuesday. CeriBell has a one year low of $23.00 and a one year high of $29.53.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.